| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$235.1M | ROE | −163.80% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $1.81B | Trading Days | 87 |
| 52W High | 34.89 |
| 52W Low | 16.50 |
| % Off High | −15.68% |
| Ann. Volatility (1Y) | 93.05% | Ann. Volatility (3Y) | 93.05% |
| Sharpe (1Y) | 0.90 | Sharpe (3Y) | 0.90 |
| Max Drawdown (1Y) | −31.21% | Max Drawdown (3Y) | −31.21% |
| YTD | 15.33% | Since inception | 15.33% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | $1.82B | — |
| STOK | Stoke Therapeutics, Inc. | $1.83B | — |
| BCAX | Bicara Therapeutics Inc. | $1.83B | — |
| TYRA | Tyra Biosciences, Inc. | $1.85B | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.89B | — |
| GENB | Generate Biomedicines, Inc. | $1.72B | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.91B | 23.6 |
| SLN | Silence Therapeutics plc | $1.71B | — |
| PGEN | PRECIGEN, INC. | $1.93B | — |
| ZYME | Zymeworks Inc. | $1.68B | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.68B |
| — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.96B | 7.4 |
